摘要
目的:探讨超选择性支气管动脉栓塞化疗(BACE)在难治性非小细胞肺癌(NSCLC)中的治疗效果。方法:选取2014年1月-2017年6月在医院治疗的难治性NSCLC患者152例资料回顾性分析。依据所使用的治疗方法分组,采用单纯支气管动脉灌注化疗的患者作为对照组,采用超选择性BACE治疗患者作为观察组。对比两组的近期(治疗3个月)治疗效果、生存情况、不良反应情况。结果:观察组90例患者,对照组62例患者。观察组的近期治疗效果、治疗总有效率优于对照组(P<0.05)。对照组平均生存时间24.424个月,观察组平均生存时间28.447个月,差异有统计学意义(Log-rank X^2=4.008,P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:使用超选择性BACE治疗难治性NSCLC患者,有助于提升治疗效果,改善患者的生存情况,具有良好的安全性。
Objective:To explore the therapeutic effect of superselective bronchial artery chemoembolization(BACE)in refractory non-small cell lung cancer(NSCLC).Method:The data of 152 patients with refractory NSCLC who were treated in the hospital from January 2014 to June 2017 were selected for retrospective analysis.According to the treatment methods used by the patients,patients treated with bronchial arterial infusion chemotherapy alone as the control group,and patients treated with superselective BACE as the observation group.The short-term(3 months of treatment)treatment effect,the survival and the adverse reactions were compared between the two groups during the treatment.Result:There were 90 patients in the observation group,and 62 patients in the control group.The short-term treatment effect and total therapeutic effective rate of the observation group were better than those of the control group(P<0.05).The average survival time of the control group was 24.424 months,and the average survival time of the observation group was 28.447 months,the difference was statistically significant(Log-rank X^2=4.008,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups during the treatment(P>0.05).Conclusion:The use of super-selective BACE to treat patients with refractory NSCLC is helpful to enhance the therapeutic effect,improve the patients’survival,and has good safety.
作者
吴丽
王海荣
李娜
杨鲜
李韵
WU Li;WANG Hairong;LI Na;YANG Xian;LI Yun(Suining Central Hospital,Suining 629000,China;不详)
出处
《中外医学研究》
2020年第29期136-138,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
超选择性支气管动脉栓塞化疗
非小细胞肺癌
手术
血管
生存时间
Superselective bronchial artery chemoembolization
Non-small cell lung cancer
Surgery
Blood vessel
Survival time
